News

[The Future of in vitro Pharmacology]

Mechanistic understanding of the interactions between drugs and human physiology is essential for developing safe and efficacious therapies. As therapeutic modalities become more complex, traditional preclinical models are proving inadequate. The lack of human-specificity in animal models and the limited complexity of standard in vitro systems drive up R&D costs and increase the risk of late-stage clinical attrition.

Javelin Biotech is redefining the preclinical standard. The Javelin platform captures both the biological complexity and human specificity required for acute and chronic drug studies across a range of drug modalities. By enabling pharmacologically-relevant studies, the platform generates the longitudinal, high-content, and clinically-relevant data and predictions required to identify efficacious and safe therapies faster—and more accurately—than traditional methods.